AbCellera (ABCL) Stock Pops 6% as Menopause Drug Hits Phase 2 Finish Line

TLDR

• ABCL stock rose 6.13%, with an earlier intraday jump of 10.3% to $6.53 following Q2 earnings and pipeline news
• Top-line Phase 2 results for ABCL635, a non-hormonal menopause treatment, will be released before market open on August 10
• Q2 revenue fell 76.3% year-over-year to $4.05 million, while net loss widened to $55.4 million
• The company holds $567 million in cash and over $675 million in available liquidity
• Partnerships with Jazz and Vertex have brought in more than $110 million in upfront cash

AbCellera Biologics (ABCL) jumped as much as 10.3% to $6.53 on August 7, closing up 6.13%, as investors reacted to Q2 earnings and an upcoming clinical data release.

AbCellera Biologics Inc., ABCL

The company announced it will release top-line Phase 2 results for ABCL635 before market open on August 10, 2026. An investor call and webcast are scheduled for 4:30 a.m. PT that morning.

ABCL635 is a potential first-in-class non-hormonal antibody targeting the NK3 receptor, designed to reduce the frequency and severity of vasomotor symptoms in postmenopausal women. It entered the clinic in July 2025.

… Continue reading the full article at the original source below.